Clinical Technology Consolidation

In a recent video interview with Applied Clinical Trials, Jeff Sidell, PhD, chief technology officer, Advarra, discussed current challenges in clinical research technology. He highlighted the overabundance of systems and emphasized the need for integration to streamline processes and reduce administrative overhead. Sidell also discussed the potential of AI, particularly predictive analytics, to automate repetitive tasks, enhancing efficiency and quality.

A transcript of Sidell’s conversation with ACT can be found below.

ACT: Looking forward five years, where do you think industry will be with adopting more clinical technology?

Sidell: I don't think there's going to be literally more technology. If you look at it, there are products, many products, in some cases, from the very beginning to the very end, from drug discovery all the way through to Phase IV and follow ups for clinical trials. I think what you will see, though, is, I think there will be a consolidation. I've seen this in other industries—banking, manufacturing, things like that—where you'll see a consolidation of technologies. It's actually less technology, but technology that is more effective, because the systems will work more seamlessly together. That's my hope, anyway. It’s a really, really populated space right now, there are almost too many products, too many to choose from. Everybody's vying to be number one in their particular area. Hopefully that landscape is going to become simplified, and that will lead to more seamless utilization of technologies in the clinical trial space.